Evaluation of the Potential Impact of In Silico Humanization on VHH Dynamics

Camelids have the peculiarity of having classical antibodies composed of heavy and light chains as well as single-chain antibodies. They have lost their light chains and one heavy-chain domain. This evolutionary feature means that their terminal heavy-chain domain, VH, called VHH here, has no partner and forms an independent domain. The VHH is small and easy to express alone; it retains thermodynamic and interaction properties. Consequently, VHHs have garnered significant interest from both biotechnological and pharmaceutical perspectives. However, due to their origin in camelids, they cannot be used directly on humans. A humanization step is needed before a possible use. However, changes, even in the constant parts of the antibodies, can lead to a loss of quality. A dedicated tool, Llamanade, has recently been made available to the scientific community. In a previous paper, we already showed the different types of VHH dynamics. Here, we have selected a representative VHH and tested two humanization hypotheses to accurately assess the potential impact of these changes. This example shows that despite the non-negligible change (1/10th of residues) brought about by humanization, the effect is not drastic, and the humanized VHH retains conformational properties quite similar to those of the camelid VHH.

[1]  Yoshiya Tanaka Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis , 2023, Expert opinion on biological therapy.

[2]  N. Sookrung,et al.  Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies , 2023, Viruses.

[3]  A. D. de Brevern,et al.  Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia , 2023, Biomolecules.

[4]  S. Magez,et al.  NANOBODIES®: A Review of Generation, Diagnostics and Therapeutics , 2023, International journal of molecular sciences.

[5]  Akhila Melarkode Vattekatte,et al.  General Trends of the Camelidae Antibody VHHs Domain Dynamics , 2023, International journal of molecular sciences.

[6]  E. Moreno,et al.  NbThermo: a new thermostability database for nanobodies , 2023, Database J. Biol. Databases Curation.

[7]  S. Keam Ozoralizumab: First Approval , 2022, Drugs.

[8]  D. Schneidman-Duhovny,et al.  NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning , 2022, Frontiers in Immunology.

[9]  T. Takeuchi,et al.  Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis , 2022, Arthritis & rheumatology.

[10]  C. Chia,et al.  A Patent Review on FDA‐Approved Antibody‐Drug Conjugates, Their Linkers and Drug Payloads , 2022, ChemMedChem.

[11]  Nicolas K. Shinada,et al.  VHH Structural Modelling Approaches: A Critical Review , 2022, International journal of molecular sciences.

[12]  Miwa Sato,et al.  Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics , 2022, Antibodies.

[13]  Akhila Melarkode Vattekatte,et al.  Insights into Comparative Modeling of VHH Domains , 2021, International journal of molecular sciences.

[14]  I. Bahar,et al.  Llamanade: an open-source computational pipeline for robust nanobody humanization , 2021, bioRxiv.

[15]  M. Diamond,et al.  SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses , 2021, Nature.

[16]  D. Ho,et al.  Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants , 2021, Nature.

[17]  Yanmin Xu,et al.  Bispecific Antibodies: From Research to Clinical Application , 2021, Frontiers in Immunology.

[18]  Kevin A. Henry,et al.  Immunogenicity and humanization of single‐domain antibodies , 2021, The FEBS journal.

[19]  A. D. de Brevern,et al.  Analysis of Protein Disorder Predictions in the Light of a Protein Structural Alphabet , 2020, Biomolecules.

[20]  Jean-Christophe Gelly,et al.  Discrete analysis of camelid variable domains: sequences, structures, and in-silico structure prediction , 2020, PeerJ.

[21]  Nicolas K. Shinada,et al.  A structural entropy index to analyse local conformations in Intrinsically Disordered Proteins. , 2020, Journal of structural biology.

[22]  S. Muyldermans,et al.  The Therapeutic Potential of Nanobodies , 2019, BioDrugs.

[23]  Nicolas K. Shinada,et al.  Discrete analyses of protein dynamics , 2019, Journal of biomolecular structure & dynamics.

[24]  Flora Peyvandi,et al.  Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura , 2019, The New England journal of medicine.

[25]  Lucy J. Colwell,et al.  Comparative analysis of nanobody sequence and structure data , 2018, Proteins.

[26]  Christopher J. Williams,et al.  MolProbity: More and better reference data for improved all‐atom structure validation , 2018, Protein science : a publication of the Protein Society.

[27]  A. D. de Brevern,et al.  In silico analysis of Glanzmann variants of Calf-1 domain of αIIbβ3 integrin revealed dynamic allosteric effect , 2017, Scientific Reports.

[28]  A. D. de Brevern,et al.  PBxplore: a tool to analyze local protein structure and deformability with Protein Blocks , 2017, bioRxiv.

[29]  James Hetherington,et al.  abYsis: Integrated Antibody Sequence and Structure-Management, Analysis, and Prediction. , 2017, Journal of molecular biology.

[30]  A. Malpertuy,et al.  Global analysis of VHHs framework regions with a structural alphabet. , 2016, Biochimie.

[31]  Bohdan Schneider,et al.  Protein flexibility in the light of structural alphabets , 2015, Front. Mol. Biosci..

[32]  Wouter G. Touw,et al.  A series of PDB-related databanks for everyday needs , 2014, Nucleic Acids Res..

[33]  Jean-Christophe Gelly,et al.  mulPBA: an efficient multiple protein structure alignment method based on a structural alphabet , 2014, Journal of biomolecular structure & dynamics.

[34]  Jing Huang,et al.  CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data , 2013, J. Comput. Chem..

[35]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[36]  O. Bertrand,et al.  Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine? , 2012, Postepy higieny i medycyny doswiadczalnej.

[37]  N. Srinivasan,et al.  Improvement of protein structure comparison using a structural alphabet. , 2011, Biochimie.

[38]  C. Etchebest,et al.  Multiple interests in structural models of DARC transmembrane protein. , 2010, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[39]  Bohdan Schneider,et al.  A short survey on protein blocks , 2010, Biophysical Reviews.

[40]  A. G. Brevern,et al.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines , 2010, Cellular and Molecular Life Sciences.

[41]  Roland L. Dunbrack,et al.  Improved prediction of protein side‐chain conformations with SCWRL4 , 2009, Proteins.

[42]  Catherine Etchebest,et al.  A new prediction strategy for long local protein structures using an original description , 2009, Proteins.

[43]  Charles Duyckaerts,et al.  Llama VHH antibody fragments against GFAP: better diffusion in fixed tissues than classical monoclonal antibodies , 2009, Acta Neuropathologica.

[44]  Andrew C. R. Martin,et al.  Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. , 2008, Molecular immunology.

[45]  M. Tyagi,et al.  Local Protein Structures , 2007 .

[46]  S. Kashanian,et al.  Studies of thermostability in Camelus bactrianus (Bactrian camel) single‐domain antibody specific for the mutant epidermal‐growth‐factor receptor expressed by Pichia , 2007, Biotechnology and applied biochemistry.

[47]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[48]  J. Skolnick,et al.  TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.

[49]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[50]  Christopher M. Dobson,et al.  A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme , 2003, Nature.

[51]  H. Valadié,et al.  Extension of a local backbone description using a structural alphabet: A new approach to the sequence‐structure relationship , 2002, Protein science : a publication of the Protein Society.

[52]  V. Shankar,et al.  Therapeutic Applications of Monoclonal Antibodies , 2002, The American Journal of the Medical Sciences.

[53]  S. Muyldermans,et al.  Single domain camel antibodies: current status. , 2001, Journal of biotechnology.

[54]  L. Wyns,et al.  Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. , 2001, Trends in biochemical sciences.

[55]  C. Etchebest,et al.  Bayesian probabilistic approach for predicting backbone structures in terms of protein blocks , 2000, Proteins.

[56]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[57]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[58]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[59]  T. T. Wu,et al.  AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY , 1970, The Journal of experimental medicine.

[60]  S. Muyldermans,et al.  Antibody repertoire development in camelids. , 2006, Developmental and comparative immunology.

[61]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[62]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..